Literature DB >> 18672143

Management of women who have a genetic predisposition for breast cancer.

Ismail Jatoi1, William F Anderson.   

Abstract

The management of women who have a genetic predisposition for breast cancer requires careful planning. Women who have BRCA 1 and BRCA 2 mutations are at increased risk for breast cancer and for other cancers as well, particularly ovarian cancer. Screening, prophlyactic surgery, and chemoprevention are commonly utilized strategies in the management of these patients, and women may choose more than one of these strategies. No randomized prospective trials have assessed the impact of these strategies specifically in mutation carriers. All patients should be informed that screening, prophylactic surgery, and chemoprevention have the potential for harm as well as benefit.

Entities:  

Mesh:

Year:  2008        PMID: 18672143     DOI: 10.1016/j.suc.2008.04.007

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  8 in total

1.  A long AAAG repeat allele in the 5' UTR of the ERR-γ gene is correlated with breast cancer predisposition and drives promoter activity in MCF-7 breast cancer cells.

Authors:  C L Galindo; J F McCormick; V J Bubb; D H Abid Alkadem; Long-Shan Li; L J McIver; A C George; D A Boothman; J P Quinn; M A Skinner; H R Garner
Journal:  Breast Cancer Res Treat       Date:  2010-12-10       Impact factor: 4.872

2.  [Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families].

Authors:  Christian F Singer; Muy-Kheng Tea; Gunda Pristauz; Michael Hubalek; Christine Rappaport; Christopher Riedl; Thomas Helbich
Journal:  Wien Klin Wochenschr       Date:  2012-05-28       Impact factor: 1.704

Review 3.  Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

Authors:  Sandhya Pruthi; Bobbie S Gostout; Noralane M Lindor
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

4.  Serum levels of IGF-I and BRCA penetrance: a case control study in breast cancer families.

Authors:  Patrizia Pasanisi; Eleonora Bruno; Elisabetta Venturelli; Siranoush Manoukian; Monica Barile; Bernard Peissel; Clelia De Giacomi; Bernardo Bonanni; Jacopo Berrino; Franco Berrino
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

Review 5.  Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

Authors:  Ismail Jatoi
Journal:  Eur J Breast Health       Date:  2018-10-01

6.  Clinical Practice Guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families.

Authors:  C F Singer; M K Tea; G Pristauz; M Hubalek; C Rappaport; C C Riedl; T H Helbich
Journal:  Wien Klin Wochenschr       Date:  2015-11-02       Impact factor: 1.704

Review 7.  Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.

Authors:  Mohamed Salhab; Selina Bismohun; Kefah Mokbel
Journal:  BMC Womens Health       Date:  2010-10-20       Impact factor: 2.809

8.  Practical consensus recommendation on when to do BRCA testing.

Authors:  Purvish M Parikh; J Wadhwa; S Minhas; A Gupta; S Mittal; S Ranjan; P Mehta; R Singh; S P Kataria; S Salim; M Ahmed; S Aggarwal
Journal:  South Asian J Cancer       Date:  2018 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.